Ken Griffin Immunic, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.95 $6,804 - $12,285	6,300 Added 7.6%	89,200 $147,000
Q2 2024 Aug 14, 2024	BUY	$0.98 - $1.44 $7,546 - $11,088	7,700 Added 10.24%	82,900 $92,000
Q1 2024 May 15, 2024	SELL	$1.14 - $1.53 $4,446 - $5,967	-3,900 Reduced 4.93%	75,200 $99,000
Q4 2023 Feb 14, 2024	BUY	$0.97 - $1.6 $26,578 - $43,840	27,400 Added 53.0%	79,100 $118,000
Q3 2023 Nov 14, 2023	SELL	$1.35 - $2.87 $10,395 - $22,099	-7,700 Reduced 12.96%	51,700 $75,000
Q2 2023 Aug 14, 2023	SELL	$1.33 - $2.51 $47,880 - $90,359	-36,000 Reduced 37.74%	59,400 $149,000
Q1 2023 May 15, 2023	BUY	$1.35 - $2.87 $69,525 - $147,805	51,500 Added 117.31%	95,400 $142,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $22,147 - $211,680	19,600 Added 80.66%	43,900 $61,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $52,200 - $95,526	-17,400 Reduced 41.73%	24,300 $77,000

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.